Focus on the epigenome in the myeloproliferative neoplasms

Area of Science:

• Hematology
• Molecular Biology
• Epigenetics

Background:

• Myeloproliferative neoplasms (MPNs) are primarily driven by mutations activating the JAK-STAT signaling pathway, particularly JAK2.
• However, additional genetic events are suspected to influence MPN phenotype, precede JAK2 mutations, and contribute to leukemic transformation.

Purpose of the Study:

• To review the biological and clinical implications of epigenetic alterations in the pathogenesis of MPNs.
• To highlight the role of epigenetic modifiers in MPN development and progression.

Main Methods:

• Review of recent literature on genetic mutations in MPNs.
• Focus on mutations in epigenetic modifiers such as ASXL1, DNMT3A, EZH2, IDH1, IDH2, and TET2.
• Inclusion of studies investigating the direct effects of mutant JAK2 on histone modifications.

Main Results:

• Mutations in several epigenetic modifiers (ASXL1, DNMT3A, EZH2, IDH1, IDH2, TET2) have been identified in MPN patients.
• Mutant JAK2 has been shown to directly impact histone posttranslational modifications.
• Epigenetic alterations are increasingly recognized as significant contributors to MPN pathogenesis.

Conclusions:

• Epigenetic alterations represent a crucial layer of genetic events in MPN pathogenesis.
• Understanding these alterations is vital for comprehending MPN development, phenotype modification, and leukemic transformation.
• Further research into the interplay between epigenetic modifiers and signaling pathways in MPNs is warranted.